Article Details
Retrieved on: 2024-10-15 16:08:54
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses the phase II GEOMETRY mono-1 trial results, highlighting capmatinib's efficacy for non-small cell lung cancer (NSCLC) with METex14 mutations. Peripheral edema is noted as a common adverse event of the treatment.
Article found on: ascopost.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here